Jan-Olav Henck, PhD,
chief scientific officer
Jan-Olav Henck, PhD, chief scientific officer at Aptuit, discusses strategies and considerations in polymorph screening with Patricia Van Arnum, senior editor of Pharmaceutical Technology (Posted November 2011).
With deadlines only a few years away, some companies have not started serialization programs, while others are taking a tactical, short-term approach, losing out on potential business benefits.
Siegfried Schmitt, Principal Consultant, PAREXEL International, discusses how to report quality metrics to FDA.
The agency publishes draft guidance on assessing the adhesion of transdermal delivery systems and topical patches.
The company received a warning letter at its Latina facility in Sermoneta, Italy following a May 2015 inspection.
FDA approved Probuphine, the first buprenorphine implant approved in the United States for the treatment of opioid dependence.
Ingredients Insider Cynthia ChallenerUpstream and Downstream Operations Can Impact Biologic API Uniformity